Certara to Report Fourth Quarter and Full Year 2022 Financial Results on March 1st, 2023 Press Release 3 月 1 日发布的 Certara 第四季度和全年财务结果报告 20222023 PRINCETON, N.J.— 2023 年 2 月 1 日-- Certara, Inc. (纳斯达克股票代码:CERT), a global leader in biosimulation, today…Jim Gallagher2023 年 2 月 1 日
Use of Secondary Intelligence™ to predict QTc interval prolongation in humans from hERG margin data Poster 使用 Secondary Intelligence™ 根据 hERG 边际数据预测人体 QTc 间期延长 Danielle Pillsbury2023 年 2 月 1 日
Use of Secondary Intelligence™ to Predict Postural Hypotension in Humans Using Alpha-1A Adrenoceptor Binding Data Poster 利用 Alpha-1A 肾上腺素受体结合数据,通过 Secondary Intelligence™ 预测人体体位性低血压 Danielle Pillsbury2023 年 2 月 1 日
How Modeling & Simulation is Addressing the Immunogenicity Challenge: An academic nicety is now a drug development and regulatory differentiator White Paper How Modeling & Simulation is Addressing the Immunogenicity Challenge: An academic nicety is now a drug development and regulatory differentiator Learn how modeling and simulation can help drug developers overcome the immunogenicity challenge, a major…Piet van der Graaf and Andrzej Kierzek2023 年 1 月 30 日
《通货膨胀削减法》会影响药物开发决策吗? 博客 《通货膨胀削减法》会影响药物开发决策吗? The short answer is yes. In fact, passage of the Inflation Reduction Act (H.R. 5376)…Certara2023 年 1 月 27 日
How Drug Developers can Navigate the Inflation Reduction Act of 2022 White Paper How Drug Developers can Navigate the Inflation Reduction Act of 2022 Learn how the IRA will impact how new drugs are marketed and why negotiating pricing…Jim Gallagher2023 年 1 月 27 日
Exceling at Accelerating in Rare Disease Drug Development Article 在加速罕见病药物开发方面如何表现出色 By: Rajesh Krishna, PhD, FAAPS and Steve Sibley According to the National Institutes of Health,…Certara2023 年 1 月 26 日
Budget Consequences of Five Benign Prostatic Hyperplasia Treatment Options – US Medicare Perspective Poster 五种良性前列腺增生治疗方案的预算影响 — 美国医疗保险的视角 Certara2023 年 1 月 26 日
Exposure-Response Analyses of Tremelimumab Monotherapy or in Combination with Durvalumab in Patients with Unresectable Hepatocellular Carcinoma Publication Exposure-Response Analyses of Tremelimumab Monotherapy or in Combination with Durvalumab in Patients with Unresectable Hepatocellular Carcinoma An novel single dose regimen of tremelimumab combined with durvalumab could be a way to…Rajesh Krishna2023 年 1 月 26 日
Tips & Tricks for Streamlining Non-compartmental Pharmacokinetic Analysis Blog 简化非房室药代动力学分析的技巧和窍门 These Phoenix tips and tricks will help you exclude Lambda Z, name partial areas, and…Certara2023 年 1 月 20 日